PCED1B (Proteasome-converting enzyme B): A Protein Expressed in Various Tissues

Target Name: PCED1B

NCBI ID: G91523

PCED1B

PCED1B (Proteasome-converting enzyme B): A Protein Expressed in Various Tissues

It is a key enzyme in the proteasome system, which is responsible for breaking down and degrading proteins that are no longer needed. PCED1B has been identified as a potential drug target and has been shown to play a role in a variety of biological processes. In this article, we will explore the biology of PCED1B and its potential as a drug target.

Background

The proteasome system is a complex organelle that is responsible for the degradation of damaged or unnecessary proteins. This system is composed of a protein complex known as the proteasome, which consists of 26 different proteins that work together to break down and degradate proteins. The proteasome system is essential for maintaining cellular homeostasis and has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

PCED1B is a key enzyme in the proteasome system that is involved in the processing and degradation of various proteins. It is a 21 kDa protein that is expressed in various tissues throughout the body, including the brain, spleen, heart, and liver. PCED1B is a member of the superfamily of core proteins, which are characterized by the presence of a single transmembrane domain and a cytoplasmic N-endopeptide.

Expression and function

PCED1B is widely expressed in various tissues and is involved in the regulation of protein degradation. In the brain, PCED1B is expressed in the astrocytes, which are a type of glial cell that support the nervous system. In these cells, PCED1B is involved in the degradation of beta-amyloid peptides, which are thought to contribute to the development of Alzheimer's disease.

In addition to its role in protein degradation, PCED1B is also involved in the regulation of protein synthesis. It has been shown to play a role in the regulation of the translation of certain genes, including the genes encoding neurotransmitter receptors. This suggests that PCED1B may be involved in the regulation of neurotransmitter signaling, which is important for various physiological processes in the brain.

Drug targeting

PCED1B is a potential drug target because of its involvement in the proteasome system and its ability to interact with a variety of small molecules. Many drugs that are currently in use, including anti-inflammatory drugs and neurotransmitter reuptake inhibitors, target proteins that are involved in the proteasome system or the regulation of protein synthesis. Therefore, targeting PCED1B may be a promising strategy for the development of new drugs for a variety of diseases.

Conclusion

In conclusion, PCED1B is a protein that is involved in the proteasome system and has been shown to play a role in a variety of biological processes. Its potential as a drug target is due to its involvement in this system and its ability to interact with a variety of small molecules. Further research is needed to fully understand the biology of PCED1B and its potential as a drug target.

Protein Name: PC-esterase Domain Containing 1B

The "PCED1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCED1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets